Huijuan Chen
Huijuan Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Bing Wang
Beijing Shuimu Jiheng Biotechnology Co., Ltd Beijing P.R. China
2 shared publicationsChunyan Yang
Beijing SeqTide Gene Technology Co. Ltd, Beijing, China
2 shared publications- Dongjie Fan
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease National Institute for Communicable Disease Control and Prevention, Chinese Center For Disease Control and Prevention Beijing P.R. China
2 shared publications Henan Dong
Beijing Best HealthCare Medical Technology Co. Ltd, Beijing, China
2 shared publications- Qiming Zhou
School of Life Science and Technology, Harbin Institute of Technology, Harbin, China
2 shared publications Yiran Zhang
Beijing SeqTide Gene Technology Co. Ltd, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 24 October 2025
- Published by Wiley in Engineering in Life Sciences
- Vol. 25 (10) , e70047
A Differential Depth Sequencing Method, SPRE‐Seq, for Enhancing Targeted Region Coverage in Hybridization Capture‐Based NGS
Sequencing depth is a crucial parameter for variant calling accuracy and sensitivity. The trade‐off between sequencing breadth and depth is a well‐known limitation in capture‐based targeted next‐generation sequencing (NGS). Herein, we propose a differential depth sequencing method, SPRE‐Seq, to acquire different sequencing depths for different targeted regions in an NGS panel. The SPRE‐Seq performance was evaluated using a panel of reference standards and clinical samples based on our custom‐designed homologous recombination deficiency (HRD) assay. By applying SPRE‐Seq, the effective sequencing depths of the homologous recombination repair (HRR) and HRD regions of all seven HRD reference standards met the required thresholds with only half the sequencing data volume (reduced from 12 to 6 GB). The results for the HRR genes and HRD showed 100% consistency with the expected results. In clinical samples, the effective sequencing depth of the HRR regions was significantly higher, with a sequencing data volume of 6 GB using the SPRE‐Seq approach compared with 6 GB using a regular capture approach. However, there was no significant difference between a data volume of 6 GB using SPRE‐Seq and 12 GB using a regular capture method. The SPRE‐Seq approach was feasible and reliable for determining the HRD status and HRR somatic variants in reference standards and clinical samples at a low sequencing volume. SPRE‐Seq is a reliable, feasible, and cost‐effective method that can acquire an adequate sequencing depth of an NGS panel at a low sequencing data volume.
- 24 October 2025
- Published by Wiley in Engineering in Life Sciences
- Vol. 25 (10) , e70047
Open AccessA Differential Depth Sequencing Method, SPRE‐Seq, for Enhancing Targeted Region Coverage in Hybridization Capture‐Based NGS
Sequencing depth is a crucial parameter for variant calling accuracy and sensitivity. The trade‐off between sequencing breadth and depth is a well‐known limitation in capture‐based targeted next‐generation sequencing (NGS). Herein, we propose a differential depth sequencing method, SPRE‐Seq, to acquire different sequencing depths for different targeted regions in an NGS panel. The SPRE‐Seq performance was evaluated using a panel of reference standards and clinical samples based on our custom‐designed homologous recombination deficiency (HRD) assay. By applying SPRE‐Seq, the effective sequencing depths of the homologous recombination repair (HRR) and HRD regions of all seven HRD reference standards met the required thresholds with only half the sequencing data volume (reduced from 12 to 6 GB). The results for the HRR genes and HRD showed 100% consistency with the expected results. In clinical samples, the effective sequencing depth of the HRR regions was significantly higher, with a sequencing data volume of 6 GB using the SPRE‐Seq approach compared with 6 GB using a regular capture approach. However, there was no significant difference between a data volume of 6 GB using SPRE‐Seq and 12 GB using a regular capture method. The SPRE‐Seq approach was feasible and reliable for determining the HRD status and HRR somatic variants in reference standards and clinical samples at a low sequencing volume. SPRE‐Seq is a reliable, feasible, and cost‐effective method that can acquire an adequate sequencing depth of an NGS panel at a low sequencing data volume.
- Open Access
- 14 February 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-13
Distinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers
Lung cancer (LC) remains the leading cause of cancer death globally. Recent reports have suggested that circulating microbial nucleic acids have potential as promising biomarkers for cancer liquid biopsies. However, circulating microbial profiles and their potential clinical value in LC patients remained unexplored. In this study, plasma samples from 76 LC patients, 9 liver cancer patients, 11 pancreatic cancer patients, and 53 healthy controls (HCs) were collected and underwent metagenomic analyses by whole genome sequencing. The composition and relative abundance of the microbial profiles were significantly different between the LC patients and HCs. A distinct plasma-based microbial profile was observed in LC patients. By differential analysis using MaAslin, 40 significant species between LC patients and HCs were identified. Five species were selected as optimal circulating microbial biomarkers for LC. The constructed classifier based on these five species showed an AUC of 0.9592, 0.9131, and 0.8077 in the discovery, validation, and additional validation cohorts, respectively. Furthermore, metagenomic profiles of 25 lung tumor tissue and plasma paired samples were analyzed and compared. The microbial diversity was significantly increased in plasma compared with the tumor tissue. Among the 13 shared core microbial species, 10 had no difference between the tumor tissue and paired plasma. In conclusion, circulating microbial nucleic acids in the plasma have potential as biomarkers for LC liquid biopsies. The microbiome in the tumor tissue was one of the possible sources of circulating microbial nucleic acids.
- 14 February 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-13
Open AccessDistinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers
Lung cancer (LC) remains the leading cause of cancer death globally. Recent reports have suggested that circulating microbial nucleic acids have potential as promising biomarkers for cancer liquid biopsies. However, circulating microbial profiles and their potential clinical value in LC patients remained unexplored. In this study, plasma samples from 76 LC patients, 9 liver cancer patients, 11 pancreatic cancer patients, and 53 healthy controls (HCs) were collected and underwent metagenomic analyses by whole genome sequencing. The composition and relative abundance of the microbial profiles were significantly different between the LC patients and HCs. A distinct plasma-based microbial profile was observed in LC patients. By differential analysis using MaAslin, 40 significant species between LC patients and HCs were identified. Five species were selected as optimal circulating microbial biomarkers for LC. The constructed classifier based on these five species showed an AUC of 0.9592, 0.9131, and 0.8077 in the discovery, validation, and additional validation cohorts, respectively. Furthermore, metagenomic profiles of 25 lung tumor tissue and plasma paired samples were analyzed and compared. The microbial diversity was significantly increased in plasma compared with the tumor tissue. Among the 13 shared core microbial species, 10 had no difference between the tumor tissue and paired plasma. In conclusion, circulating microbial nucleic acids in the plasma have potential as biomarkers for LC liquid biopsies. The microbiome in the tumor tissue was one of the possible sources of circulating microbial nucleic acids.
- Open Access
- 25 October 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (19-20) , e24977
A unified DNA‐ and RNA‐based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors
Background: Targeted next‐generation sequencing (NGS) is a powerful and suitable approach to comprehensively identify multiple types of variants in tumors. RNA‐based NGS is increasingly playing an important role in precision oncology. Both parallel and sequential DNA‐ and RNA‐based approaches are expensive, burdensome, and have long turnaround times, which can be impractical in clinical practice. A streamlined, unified DNA‐ and RNA‐based NGS approach is urgently needed in clinical practice.Methods: A DNA/RNA co‐hybrid capture sequencing (DRCC‐Seq) approach was designed to capture pre‐capture DNA and RNA libraries in a single tube and convert them into one NGS library. The performance of the DRCC‐Seq approach was evaluated by a panel of reference standards and clinical samples.Results: The average depth, DNA data ratio, capture ratio, and target coverage 250 (×) of the DNA panel data had a negative correlation with an increase in the proportion of RNA probes. The SNVs, indels, fusions, and MSI status were not affected by the proportion of RNA probes, but the copy numbers of the target genes were higher than expected in the standard materials, and many unexpected gene amplifications were found using D:R (1:2) and D:R (1:4) probe panels. The optimal ratio of DNA and RNA probes in the combined probe panel was 1:1 using the DRCC‐Seq approach. The DRCC‐Seq approach was feasible and reliable for detecting multiple types of variants in reference standards and real‐world clinical samples.Conclusions: The DRCC‐Seq approach is more cost‐effective, with a shorter turnaround time and lower labor requirements than either parallel or sequential targeted DNA NGS and RNA NGS. It is feasible to identify multiple genetic variations at the DNA and RNA levels simultaneously in clinical practice.
- 25 October 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (19-20) , e24977
Open AccessA unified DNA‐ and RNA‐based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors
Background: Targeted next‐generation sequencing (NGS) is a powerful and suitable approach to comprehensively identify multiple types of variants in tumors. RNA‐based NGS is increasingly playing an important role in precision oncology. Both parallel and sequential DNA‐ and RNA‐based approaches are expensive, burdensome, and have long turnaround times, which can be impractical in clinical practice. A streamlined, unified DNA‐ and RNA‐based NGS approach is urgently needed in clinical practice.Methods: A DNA/RNA co‐hybrid capture sequencing (DRCC‐Seq) approach was designed to capture pre‐capture DNA and RNA libraries in a single tube and convert them into one NGS library. The performance of the DRCC‐Seq approach was evaluated by a panel of reference standards and clinical samples.Results: The average depth, DNA data ratio, capture ratio, and target coverage 250 (×) of the DNA panel data had a negative correlation with an increase in the proportion of RNA probes. The SNVs, indels, fusions, and MSI status were not affected by the proportion of RNA probes, but the copy numbers of the target genes were higher than expected in the standard materials, and many unexpected gene amplifications were found using D:R (1:2) and D:R (1:4) probe panels. The optimal ratio of DNA and RNA probes in the combined probe panel was 1:1 using the DRCC‐Seq approach. The DRCC‐Seq approach was feasible and reliable for detecting multiple types of variants in reference standards and real‐world clinical samples.Conclusions: The DRCC‐Seq approach is more cost‐effective, with a shorter turnaround time and lower labor requirements than either parallel or sequential targeted DNA NGS and RNA NGS. It is feasible to identify multiple genetic variations at the DNA and RNA levels simultaneously in clinical practice.
- 20 September 2022
- Published by Elsevier in Water Research
- Vol. 225, 119139
Deriving freshwater sediment quality guidelines of polycyclic aromatic hydrocarbons using method of species sensitivity distribution and application for risk assessment
- 20 September 2022
- Published by Elsevier in Water Research
- Vol. 225, 119139
Deriving freshwater sediment quality guidelines of polycyclic aromatic hydrocarbons using method of species sensitivity distribution and application for risk assessment
- Open Access
- 29 September 2021
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 15
White Matter Abnormalities in Patients With Typhoon-Related Posttraumatic Stress Disorder
Patients with posttraumatic stress disorder (PTSD) might have white matter abnormalities. However, less is known about white matter changes after exposing a specific traumatic event. The purpose of this study was to explore the abnormalities of diffusion in cerebral white matter and its relationship with the clinical symptoms in patients with PTSD by using diffusion tensor imaging (DTI). Diffusion-weighted imaging of the cerebrum was performed in typhoon survivors with (n = 27) and without PTSD (n = 33) and healthy controls (HCs) (n = 30). Differences in fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated among groups using voxel-based analysis of the DTI data. Correlations between diffusion indices and clinical symptoms in patients with PTSD were also assessed. Both patients with PTSD and trauma-exposed control (TEC) group showed increased FA in the anterior limb of the internal capsule, forceps of the corpus callosum, and corona radiata relative to the HC group. Additionally, there was a negative correlation between FA values in the white matter and the clinical symptoms. Trauma exposure may result in disruption of cerebral white matter in individuals with or without PTSD, particularly in the frontal fibers. Aberrant white matter alterations may be associated with the severity of PTSD symptoms.
- 29 September 2021
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 15
Open AccessWhite Matter Abnormalities in Patients With Typhoon-Related Posttraumatic Stress Disorder
Patients with posttraumatic stress disorder (PTSD) might have white matter abnormalities. However, less is known about white matter changes after exposing a specific traumatic event. The purpose of this study was to explore the abnormalities of diffusion in cerebral white matter and its relationship with the clinical symptoms in patients with PTSD by using diffusion tensor imaging (DTI). Diffusion-weighted imaging of the cerebrum was performed in typhoon survivors with (n = 27) and without PTSD (n = 33) and healthy controls (HCs) (n = 30). Differences in fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated among groups using voxel-based analysis of the DTI data. Correlations between diffusion indices and clinical symptoms in patients with PTSD were also assessed. Both patients with PTSD and trauma-exposed control (TEC) group showed increased FA in the anterior limb of the internal capsule, forceps of the corpus callosum, and corona radiata relative to the HC group. Additionally, there was a negative correlation between FA values in the white matter and the clinical symptoms. Trauma exposure may result in disruption of cerebral white matter in individuals with or without PTSD, particularly in the frontal fibers. Aberrant white matter alterations may be associated with the severity of PTSD symptoms.